In this issue:
Blinatumomab vs. chemotherapy for advanced B-ALL
Leukaemia remission with CD19 CAR-T-cells of defined formulation and dose
Axicabtagene ciloleucel in refractory, aggressive lymphoma
Myeloma remission with CAR-T-cells targeting BCMA
Antitumour activity of CAR-T-cells enhanced by TLR-2 costimulation
Assessing and managing CAR-T-cell toxicity
Vaccine induces polyfunctional T-cells in high-risk melanoma
Adjuvant nivolumab vs. ipilimumab in resected stage III–IV melanoma
Indoximod for advanced malignancies
Safety of nivolumab monotherapy in advanced melanoma
Outcomes after stopping nivolumab/ipilimumab for toxicity in advanced melanoma
Please login below to download this issue (PDF)